nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydralazine—CYP3A4—Topotecan—lung cancer	0.0538	0.142	CbGbCtD
Hydralazine—CYP3A4—Gefitinib—lung cancer	0.0492	0.13	CbGbCtD
Hydralazine—CYP3A4—Teniposide—lung cancer	0.0477	0.126	CbGbCtD
Hydralazine—CYP3A4—Vinorelbine—lung cancer	0.0379	0.1	CbGbCtD
Hydralazine—CYP3A4—Crizotinib—lung cancer	0.0302	0.0796	CbGbCtD
Hydralazine—CYP3A4—Erlotinib—lung cancer	0.0291	0.0768	CbGbCtD
Hydralazine—CYP3A4—Paclitaxel—lung cancer	0.0266	0.0703	CbGbCtD
Hydralazine—CYP3A4—Irinotecan—lung cancer	0.0263	0.0694	CbGbCtD
Hydralazine—CYP3A4—Vinblastine—lung cancer	0.0234	0.0617	CbGbCtD
Hydralazine—CYP3A4—Etoposide—lung cancer	0.021	0.0556	CbGbCtD
Hydralazine—CYP3A4—Docetaxel—lung cancer	0.0193	0.0508	CbGbCtD
Hydralazine—AOC3—mammary gland—lung cancer	0.0149	0.124	CbGeAlD
Hydralazine—CYP3A4—Doxorubicin—lung cancer	0.0144	0.0379	CbGbCtD
Hydralazine—RYR2—cardiac atrium—lung cancer	0.0114	0.0956	CbGeAlD
Hydralazine—AOC3—respiratory system—lung cancer	0.00992	0.0829	CbGeAlD
Hydralazine—RYR2—lung—lung cancer	0.00875	0.0731	CbGeAlD
Hydralazine—AOC3—bronchus—lung cancer	0.00816	0.0683	CbGeAlD
Hydralazine—P4HA1—respiratory system—lung cancer	0.00793	0.0663	CbGeAlD
Hydralazine—AOC3—trachea—lung cancer	0.00733	0.0613	CbGeAlD
Hydralazine—AOC3—cardiac atrium—lung cancer	0.00689	0.0576	CbGeAlD
Hydralazine—P4HA1—bronchus—lung cancer	0.00653	0.0546	CbGeAlD
Hydralazine—P4HA1—trachea—lung cancer	0.00586	0.049	CbGeAlD
Hydralazine—AOC3—bone marrow—lung cancer	0.00581	0.0486	CbGeAlD
Hydralazine—P4HA1—cardiac atrium—lung cancer	0.00551	0.046	CbGeAlD
Hydralazine—AOC3—lung—lung cancer	0.00527	0.044	CbGeAlD
Hydralazine—P4HA1—bone marrow—lung cancer	0.00465	0.0389	CbGeAlD
Hydralazine—P4HA1—lung—lung cancer	0.00421	0.0352	CbGeAlD
Hydralazine—AOC3—lymph node—lung cancer	0.0036	0.0301	CbGeAlD
Hydralazine—RYR2—Arrhythmogenic Right Ventricular Cardiomyopathy—LMNA—lung cancer	0.00352	0.0395	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—CHRNB4—lung cancer	0.00323	0.0363	CbGpPWpGaD
Hydralazine—P4HA1—lymph node—lung cancer	0.00288	0.0241	CbGeAlD
Hydralazine—CYP3A4—Felbamate Metabolism—CYP2E1—lung cancer	0.00278	0.0312	CbGpPWpGaD
Hydralazine—RYR2—Arrhythmogenic Right Ventricular Cardiomyopathy—ITGB1—lung cancer	0.0025	0.0281	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—OXTR—lung cancer	0.00249	0.0279	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—FOXM1—lung cancer	0.00245	0.0275	CbGpPWpGaD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—GNG11—lung cancer	0.0024	0.027	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—GNG11—lung cancer	0.00233	0.0262	CbGpPWpGaD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—SFN—lung cancer	0.00229	0.0257	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—SOX2—lung cancer	0.00228	0.0256	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—SFN—lung cancer	0.00222	0.0249	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—ALDOA—lung cancer	0.0022	0.0248	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—ATF3—lung cancer	0.00217	0.0244	CbGpPWpGaD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—ADCY1—lung cancer	0.00216	0.0243	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—ADCY1—lung cancer	0.00209	0.0235	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—TF—lung cancer	0.00194	0.0218	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC34A2—lung cancer	0.0019	0.0213	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC22A18—lung cancer	0.00144	0.0162	CbGpPWpGaD
Hydralazine—CYP3A4—Codeine and Morphine Metabolism—ABCC3—lung cancer	0.0014	0.0158	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—AVP—lung cancer	0.00134	0.0151	CbGpPWpGaD
Hydralazine—CYP3A4—Codeine and Morphine Metabolism—UGT1A1—lung cancer	0.00132	0.0148	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—HES1—lung cancer	0.00127	0.0143	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—IL10—lung cancer	0.00126	0.0142	CbGpPWpGaD
Hydralazine—CYP3A4—Benzo(a)pyrene metabolism—AKR1C1—lung cancer	0.00124	0.0139	CbGpPWpGaD
Hydralazine—RYR2—Stimuli-sensing channels—RAF1—lung cancer	0.00109	0.0123	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—HIF1A—lung cancer	0.00106	0.0119	CbGpPWpGaD
Hydralazine—CYP3A4—Xenobiotics—CYP2A7—lung cancer	0.000891	0.01	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—IL6R—lung cancer	0.00087	0.00977	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—CREBBP—lung cancer	0.000869	0.00976	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—ABCC3—lung cancer	0.000863	0.00969	CbGpPWpGaD
Hydralazine—CYP3A4—Irinotecan Pathway—UGT1A1—lung cancer	0.000844	0.00949	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—GNG11—lung cancer	0.000782	0.00879	CbGpPWpGaD
Hydralazine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—lung cancer	0.000772	0.00868	CbGpPWpGaD
Hydralazine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC3—lung cancer	0.000769	0.00864	CbGpPWpGaD
Hydralazine—CYP3A4—Estrogen metabolism—GSTA1—lung cancer	0.000743	0.00834	CbGpPWpGaD
Hydralazine—CYP3A4—Irinotecan Pathway—ABCG2—lung cancer	0.000732	0.00822	CbGpPWpGaD
Hydralazine—CYP3A4—Codeine and Morphine Metabolism—ABCB1—lung cancer	0.000715	0.00803	CbGpPWpGaD
Hydralazine—RYR2—Ion channel transport—RAF1—lung cancer	0.000713	0.00802	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—ADCY1—lung cancer	0.000703	0.0079	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—ABCG2—lung cancer	0.000703	0.0079	CbGpPWpGaD
Hydralazine—CYP3A4—Estrogen metabolism—UGT1A1—lung cancer	0.00069	0.00776	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—CXCL8—lung cancer	0.00069	0.00775	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—CASP3—lung cancer	0.00066	0.00742	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—TF—lung cancer	0.000654	0.00735	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—JUN—lung cancer	0.000645	0.00724	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—JUN—lung cancer	0.000641	0.00721	CbGpPWpGaD
Hydralazine—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—lung cancer	0.000618	0.00695	CbGpPWpGaD
Hydralazine—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—lung cancer	0.000599	0.00673	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—EP300—lung cancer	0.000592	0.00665	CbGpPWpGaD
Hydralazine—CYP3A4—Tryptophan metabolism—HSD17B10—lung cancer	0.000579	0.0065	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—VEGFA—lung cancer	0.00056	0.0063	CbGpPWpGaD
Hydralazine—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—lung cancer	0.000526	0.00591	CbGpPWpGaD
Hydralazine—CYP3A4—Xenobiotics—CYP2A6—lung cancer	0.000517	0.00581	CbGpPWpGaD
Hydralazine—CYP3A4—Tamoxifen metabolism—CYP2A6—lung cancer	0.000497	0.00559	CbGpPWpGaD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—lung cancer	0.000486	0.00546	CbGpPWpGaD
Hydralazine—CYP3A4—Estrogen metabolism—NQO1—lung cancer	0.000473	0.00532	CbGpPWpGaD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC3—lung cancer	0.000463	0.00521	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—AVP—lung cancer	0.000453	0.00509	CbGpPWpGaD
Hydralazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC3—lung cancer	0.000441	0.00496	CbGpPWpGaD
Hydralazine—CYP3A4—Xenobiotics—CYP2E1—lung cancer	0.00044	0.00494	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—ABCB1—lung cancer	0.000439	0.00493	CbGpPWpGaD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—UGT1A1—lung cancer	0.000436	0.0049	CbGpPWpGaD
Hydralazine—CYP3A4—Tamoxifen metabolism—CYP2E1—lung cancer	0.000423	0.00475	CbGpPWpGaD
Hydralazine—Ill-defined disorder—Paclitaxel—lung cancer	0.000417	0.00101	CcSEcCtD
Hydralazine—Anaemia—Paclitaxel—lung cancer	0.000416	0.00101	CcSEcCtD
Hydralazine—Malaise—Etoposide—lung cancer	0.000414	0.001	CcSEcCtD
Hydralazine—Agitation—Paclitaxel—lung cancer	0.000413	0.001	CcSEcCtD
Hydralazine—Headache—Vinblastine—lung cancer	0.000411	0.000997	CcSEcCtD
Hydralazine—Leukopenia—Etoposide—lung cancer	0.00041	0.000995	CcSEcCtD
Hydralazine—Purpura—Doxorubicin—lung cancer	0.00041	0.000993	CcSEcCtD
Hydralazine—Hypotension—Gemcitabine—lung cancer	0.00041	0.000993	CcSEcCtD
Hydralazine—Oedema—Cisplatin—lung cancer	0.000408	0.00099	CcSEcCtD
Hydralazine—Flushing—Docetaxel—lung cancer	0.000406	0.000985	CcSEcCtD
Hydralazine—Vomiting—Topotecan—lung cancer	0.000405	0.000983	CcSEcCtD
Hydralazine—Malaise—Paclitaxel—lung cancer	0.000405	0.000983	CcSEcCtD
Hydralazine—Cardiac failure—Doxorubicin—lung cancer	0.000405	0.000981	CcSEcCtD
Hydralazine—Paraesthesia—Irinotecan—lung cancer	0.000404	0.000979	CcSEcCtD
Hydralazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—lung cancer	0.000404	0.00454	CbGpPWpGaD
Hydralazine—Leukopenia—Paclitaxel—lung cancer	0.000402	0.000975	CcSEcCtD
Hydralazine—Rash—Topotecan—lung cancer	0.000402	0.000975	CcSEcCtD
Hydralazine—Hypersensitivity—Vinorelbine—lung cancer	0.000402	0.000974	CcSEcCtD
Hydralazine—Dermatitis—Topotecan—lung cancer	0.000402	0.000974	CcSEcCtD
Hydralazine—Vomiting—Erlotinib—lung cancer	0.000401	0.000972	CcSEcCtD
Hydralazine—Dyspnoea—Irinotecan—lung cancer	0.000401	0.000972	CcSEcCtD
Hydralazine—Thrombocytopenia—Cisplatin—lung cancer	0.0004	0.000969	CcSEcCtD
Hydralazine—Headache—Topotecan—lung cancer	0.000399	0.000968	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Gemcitabine—lung cancer	0.000399	0.000968	CcSEcCtD
Hydralazine—Tachycardia—Cisplatin—lung cancer	0.000399	0.000966	CcSEcCtD
Hydralazine—Rash—Erlotinib—lung cancer	0.000398	0.000964	CcSEcCtD
Hydralazine—Dermatitis—Erlotinib—lung cancer	0.000397	0.000963	CcSEcCtD
Hydralazine—Palpitations—Paclitaxel—lung cancer	0.000397	0.000963	CcSEcCtD
Hydralazine—Dyspepsia—Irinotecan—lung cancer	0.000396	0.00096	CcSEcCtD
Hydralazine—Headache—Erlotinib—lung cancer	0.000395	0.000958	CcSEcCtD
Hydralazine—Paraesthesia—Gemcitabine—lung cancer	0.000394	0.000954	CcSEcCtD
Hydralazine—Chills—Docetaxel—lung cancer	0.000393	0.000952	CcSEcCtD
Hydralazine—Decreased appetite—Irinotecan—lung cancer	0.000391	0.000948	CcSEcCtD
Hydralazine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—lung cancer	0.000391	0.00439	CbGpPWpGaD
Hydralazine—Dyspnoea—Gemcitabine—lung cancer	0.000391	0.000947	CcSEcCtD
Hydralazine—Eosinophilia—Methotrexate—lung cancer	0.00039	0.000946	CcSEcCtD
Hydralazine—Nausea—Vinblastine—lung cancer	0.00039	0.000945	CcSEcCtD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—IL6—lung cancer	0.000389	0.00438	CbGpPWpGaD
Hydralazine—Anorexia—Cisplatin—lung cancer	0.000389	0.000944	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Irinotecan—lung cancer	0.000388	0.000942	CcSEcCtD
Hydralazine—RYR2—SIDS Susceptibility Pathways—IL6—lung cancer	0.000387	0.00435	CbGpPWpGaD
Hydralazine—Pruritus—Vinorelbine—lung cancer	0.000386	0.000936	CcSEcCtD
Hydralazine—Discomfort—Etoposide—lung cancer	0.000386	0.000935	CcSEcCtD
Hydralazine—Constipation—Irinotecan—lung cancer	0.000385	0.000933	CcSEcCtD
Hydralazine—Myalgia—Paclitaxel—lung cancer	0.000383	0.000928	CcSEcCtD
Hydralazine—Arthralgia—Paclitaxel—lung cancer	0.000383	0.000928	CcSEcCtD
Hydralazine—Hypotension—Cisplatin—lung cancer	0.000382	0.000925	CcSEcCtD
Hydralazine—Anxiety—Paclitaxel—lung cancer	0.000381	0.000925	CcSEcCtD
Hydralazine—Decreased appetite—Gemcitabine—lung cancer	0.000381	0.000923	CcSEcCtD
Hydralazine—Nausea—Topotecan—lung cancer	0.000379	0.000918	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000378	0.000917	CcSEcCtD
Hydralazine—Discomfort—Paclitaxel—lung cancer	0.000378	0.000917	CcSEcCtD
Hydralazine—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—lung cancer	0.000378	0.00424	CbGpPWpGaD
Hydralazine—Constipation—Gemcitabine—lung cancer	0.000375	0.000908	CcSEcCtD
Hydralazine—Nausea—Erlotinib—lung cancer	0.000375	0.000908	CcSEcCtD
Hydralazine—Pancytopenia—Methotrexate—lung cancer	0.000374	0.000907	CcSEcCtD
Hydralazine—Diarrhoea—Vinorelbine—lung cancer	0.000373	0.000905	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000372	0.000902	CcSEcCtD
Hydralazine—Feeling abnormal—Irinotecan—lung cancer	0.000371	0.000899	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—lung cancer	0.00037	0.00416	CbGpPWpGaD
Hydralazine—Dysuria—Methotrexate—lung cancer	0.000369	0.000893	CcSEcCtD
Hydralazine—Neutropenia—Methotrexate—lung cancer	0.000369	0.000893	CcSEcCtD
Hydralazine—Oedema—Paclitaxel—lung cancer	0.000367	0.000889	CcSEcCtD
Hydralazine—Paraesthesia—Cisplatin—lung cancer	0.000367	0.000889	CcSEcCtD
Hydralazine—Thrombocytopenia—Etoposide—lung cancer	0.000366	0.000888	CcSEcCtD
Hydralazine—Muscle spasms—Docetaxel—lung cancer	0.000366	0.000888	CcSEcCtD
Hydralazine—Tachycardia—Etoposide—lung cancer	0.000365	0.000885	CcSEcCtD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—lung cancer	0.000365	0.0041	CbGpPWpGaD
Hydralazine—Dyspnoea—Cisplatin—lung cancer	0.000364	0.000883	CcSEcCtD
Hydralazine—CYP3A4—Estrogen metabolism—GSTM1—lung cancer	0.000363	0.00408	CbGpPWpGaD
Hydralazine—Feeling abnormal—Gemcitabine—lung cancer	0.000361	0.000875	CcSEcCtD
Hydralazine—Dizziness—Vinorelbine—lung cancer	0.000361	0.000874	CcSEcCtD
Hydralazine—Thrombocytopenia—Paclitaxel—lung cancer	0.000359	0.000871	CcSEcCtD
Hydralazine—Tachycardia—Paclitaxel—lung cancer	0.000358	0.000868	CcSEcCtD
Hydralazine—Anorexia—Etoposide—lung cancer	0.000357	0.000865	CcSEcCtD
Hydralazine—Body temperature increased—Irinotecan—lung cancer	0.000356	0.000862	CcSEcCtD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—lung cancer	0.000355	0.00399	CbGpPWpGaD
Hydralazine—Decreased appetite—Cisplatin—lung cancer	0.000355	0.000861	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Cisplatin—lung cancer	0.000353	0.000855	CcSEcCtD
Hydralazine—Anaemia—Docetaxel—lung cancer	0.000352	0.000854	CcSEcCtD
Hydralazine—Depression—Methotrexate—lung cancer	0.00035	0.000849	CcSEcCtD
Hydralazine—Anorexia—Paclitaxel—lung cancer	0.00035	0.000848	CcSEcCtD
Hydralazine—Hypotension—Etoposide—lung cancer	0.00035	0.000848	CcSEcCtD
Hydralazine—Vomiting—Vinorelbine—lung cancer	0.000347	0.000841	CcSEcCtD
Hydralazine—RYR2—Transmembrane transport of small molecules—APOA1—lung cancer	0.000346	0.00389	CbGpPWpGaD
Hydralazine—Body temperature increased—Gemcitabine—lung cancer	0.000346	0.00084	CcSEcCtD
Hydralazine—Rash—Vinorelbine—lung cancer	0.000344	0.000834	CcSEcCtD
Hydralazine—CYP3A4—Estrogen metabolism—CYP1A1—lung cancer	0.000344	0.00386	CbGpPWpGaD
Hydralazine—Dermatitis—Vinorelbine—lung cancer	0.000344	0.000833	CcSEcCtD
Hydralazine—Hypotension—Paclitaxel—lung cancer	0.000343	0.000831	CcSEcCtD
Hydralazine—Headache—Vinorelbine—lung cancer	0.000342	0.000828	CcSEcCtD
Hydralazine—Conjunctivitis—Methotrexate—lung cancer	0.000342	0.000828	CcSEcCtD
Hydralazine—Leukopenia—Docetaxel—lung cancer	0.000341	0.000827	CcSEcCtD
Hydralazine—Eosinophilia—Doxorubicin—lung cancer	0.000338	0.000819	CcSEcCtD
Hydralazine—Palpitations—Docetaxel—lung cancer	0.000337	0.000816	CcSEcCtD
Hydralazine—Feeling abnormal—Cisplatin—lung cancer	0.000337	0.000816	CcSEcCtD
Hydralazine—Paraesthesia—Etoposide—lung cancer	0.000336	0.000815	CcSEcCtD
Hydralazine—Haematuria—Methotrexate—lung cancer	0.000335	0.000812	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000334	0.00081	CcSEcCtD
Hydralazine—Dyspnoea—Etoposide—lung cancer	0.000334	0.000809	CcSEcCtD
Hydralazine—Angina pectoris—Doxorubicin—lung cancer	0.000332	0.000806	CcSEcCtD
Hydralazine—Hypersensitivity—Irinotecan—lung cancer	0.000331	0.000803	CcSEcCtD
Hydralazine—Paraesthesia—Paclitaxel—lung cancer	0.000329	0.000799	CcSEcCtD
Hydralazine—CYP3A4—Irinotecan Pathway—APC—lung cancer	0.000329	0.0037	CbGpPWpGaD
Hydralazine—Agranulocytosis—Methotrexate—lung cancer	0.000328	0.000795	CcSEcCtD
Hydralazine—Dyspnoea—Paclitaxel—lung cancer	0.000327	0.000793	CcSEcCtD
Hydralazine—Decreased appetite—Etoposide—lung cancer	0.000325	0.000789	CcSEcCtD
Hydralazine—Myalgia—Docetaxel—lung cancer	0.000324	0.000786	CcSEcCtD
Hydralazine—Arthralgia—Docetaxel—lung cancer	0.000324	0.000786	CcSEcCtD
Hydralazine—Pancytopenia—Doxorubicin—lung cancer	0.000324	0.000786	CcSEcCtD
Hydralazine—Nausea—Vinorelbine—lung cancer	0.000324	0.000785	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Etoposide—lung cancer	0.000323	0.000783	CcSEcCtD
Hydralazine—Dyspepsia—Paclitaxel—lung cancer	0.000323	0.000783	CcSEcCtD
Hydralazine—Body temperature increased—Cisplatin—lung cancer	0.000323	0.000783	CcSEcCtD
Hydralazine—Constipation—Etoposide—lung cancer	0.00032	0.000776	CcSEcCtD
Hydralazine—Neutropenia—Doxorubicin—lung cancer	0.000319	0.000774	CcSEcCtD
Hydralazine—Dysuria—Doxorubicin—lung cancer	0.000319	0.000774	CcSEcCtD
Hydralazine—Decreased appetite—Paclitaxel—lung cancer	0.000319	0.000773	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000317	0.000768	CcSEcCtD
Hydralazine—CYP3A4—Xenobiotics—CYP1A1—lung cancer	0.000316	0.00355	CbGpPWpGaD
Hydralazine—Hepatitis—Methotrexate—lung cancer	0.000316	0.000765	CcSEcCtD
Hydralazine—Constipation—Paclitaxel—lung cancer	0.000314	0.000761	CcSEcCtD
Hydralazine—Oedema—Docetaxel—lung cancer	0.000311	0.000754	CcSEcCtD
Hydralazine—Pruritus—Gemcitabine—lung cancer	0.00031	0.000752	CcSEcCtD
Hydralazine—Weight decreased—Doxorubicin—lung cancer	0.000309	0.000749	CcSEcCtD
Hydralazine—Feeling abnormal—Etoposide—lung cancer	0.000308	0.000748	CcSEcCtD
Hydralazine—Diarrhoea—Irinotecan—lung cancer	0.000308	0.000746	CcSEcCtD
Hydralazine—Thrombocytopenia—Docetaxel—lung cancer	0.000305	0.000738	CcSEcCtD
Hydralazine—CYP3A4—Tamoxifen metabolism—CYP1A1—lung cancer	0.000304	0.00341	CbGpPWpGaD
Hydralazine—Tachycardia—Docetaxel—lung cancer	0.000304	0.000736	CcSEcCtD
Hydralazine—Feeling abnormal—Paclitaxel—lung cancer	0.000302	0.000733	CcSEcCtD
Hydralazine—Hypersensitivity—Cisplatin—lung cancer	0.000301	0.00073	CcSEcCtD
Hydralazine—Diarrhoea—Gemcitabine—lung cancer	0.0003	0.000727	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—lung cancer	0.0003	0.00337	CbGpPWpGaD
Hydralazine—Neuropathy peripheral—Doxorubicin—lung cancer	0.000298	0.000723	CcSEcCtD
Hydralazine—Dizziness—Irinotecan—lung cancer	0.000298	0.000721	CcSEcCtD
Hydralazine—Urticaria—Etoposide—lung cancer	0.000297	0.000721	CcSEcCtD
Hydralazine—Jaundice—Doxorubicin—lung cancer	0.000297	0.000719	CcSEcCtD
Hydralazine—Anorexia—Docetaxel—lung cancer	0.000296	0.000719	CcSEcCtD
Hydralazine—Body temperature increased—Etoposide—lung cancer	0.000296	0.000717	CcSEcCtD
Hydralazine—Conjunctivitis—Doxorubicin—lung cancer	0.000296	0.000717	CcSEcCtD
Hydralazine—RYR2—Transmembrane transport of small molecules—CREBBP—lung cancer	0.000293	0.0033	CbGpPWpGaD
Hydralazine—Urticaria—Paclitaxel—lung cancer	0.000291	0.000707	CcSEcCtD
Hydralazine—Hypotension—Docetaxel—lung cancer	0.000291	0.000704	CcSEcCtD
Hydralazine—Haematuria—Doxorubicin—lung cancer	0.00029	0.000703	CcSEcCtD
Hydralazine—Body temperature increased—Paclitaxel—lung cancer	0.00029	0.000703	CcSEcCtD
Hydralazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—lung cancer	0.000288	0.00323	CbGpPWpGaD
Hydralazine—Vomiting—Irinotecan—lung cancer	0.000286	0.000693	CcSEcCtD
Hydralazine—Agranulocytosis—Doxorubicin—lung cancer	0.000284	0.000688	CcSEcCtD
Hydralazine—Rash—Irinotecan—lung cancer	0.000284	0.000688	CcSEcCtD
Hydralazine—Dermatitis—Irinotecan—lung cancer	0.000283	0.000687	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000283	0.000687	CcSEcCtD
Hydralazine—Chills—Methotrexate—lung cancer	0.000283	0.000686	CcSEcCtD
Hydralazine—Headache—Irinotecan—lung cancer	0.000282	0.000683	CcSEcCtD
Hydralazine—Diarrhoea—Cisplatin—lung cancer	0.000279	0.000677	CcSEcCtD
Hydralazine—Paraesthesia—Docetaxel—lung cancer	0.000279	0.000677	CcSEcCtD
Hydralazine—Vomiting—Gemcitabine—lung cancer	0.000279	0.000675	CcSEcCtD
Hydralazine—Dyspnoea—Docetaxel—lung cancer	0.000277	0.000672	CcSEcCtD
Hydralazine—Rash—Gemcitabine—lung cancer	0.000276	0.00067	CcSEcCtD
Hydralazine—Dermatitis—Gemcitabine—lung cancer	0.000276	0.000669	CcSEcCtD
Hydralazine—Hypersensitivity—Etoposide—lung cancer	0.000276	0.000668	CcSEcCtD
Hydralazine—Headache—Gemcitabine—lung cancer	0.000275	0.000665	CcSEcCtD
Hydralazine—RYR2—Transmembrane transport of small molecules—ALB—lung cancer	0.000275	0.00308	CbGpPWpGaD
Hydralazine—Dyspepsia—Docetaxel—lung cancer	0.000274	0.000664	CcSEcCtD
Hydralazine—Hepatitis—Doxorubicin—lung cancer	0.000273	0.000662	CcSEcCtD
Hydralazine—Hypoaesthesia—Doxorubicin—lung cancer	0.000272	0.000659	CcSEcCtD
Hydralazine—Decreased appetite—Docetaxel—lung cancer	0.00027	0.000655	CcSEcCtD
Hydralazine—Hypersensitivity—Paclitaxel—lung cancer	0.00027	0.000655	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Docetaxel—lung cancer	0.000269	0.000651	CcSEcCtD
Hydralazine—Nausea—Irinotecan—lung cancer	0.000267	0.000648	CcSEcCtD
Hydralazine—Constipation—Docetaxel—lung cancer	0.000266	0.000645	CcSEcCtD
Hydralazine—Pruritus—Etoposide—lung cancer	0.000265	0.000642	CcSEcCtD
Hydralazine—Nausea—Gemcitabine—lung cancer	0.00026	0.000631	CcSEcCtD
Hydralazine—Vomiting—Cisplatin—lung cancer	0.00026	0.00063	CcSEcCtD
Hydralazine—Pruritus—Paclitaxel—lung cancer	0.00026	0.000629	CcSEcCtD
Hydralazine—Rash—Cisplatin—lung cancer	0.000258	0.000624	CcSEcCtD
Hydralazine—Dermatitis—Cisplatin—lung cancer	0.000257	0.000624	CcSEcCtD
Hydralazine—Feeling abnormal—Docetaxel—lung cancer	0.000256	0.000621	CcSEcCtD
Hydralazine—Diarrhoea—Etoposide—lung cancer	0.000256	0.000621	CcSEcCtD
Hydralazine—Ill-defined disorder—Methotrexate—lung cancer	0.000255	0.000618	CcSEcCtD
Hydralazine—Anaemia—Methotrexate—lung cancer	0.000254	0.000615	CcSEcCtD
Hydralazine—Flushing—Doxorubicin—lung cancer	0.000254	0.000615	CcSEcCtD
Hydralazine—Diarrhoea—Paclitaxel—lung cancer	0.000251	0.000609	CcSEcCtD
Hydralazine—RYR2—Transmembrane transport of small molecules—RAF1—lung cancer	0.000248	0.00279	CbGpPWpGaD
Hydralazine—Malaise—Methotrexate—lung cancer	0.000248	0.0006	CcSEcCtD
Hydralazine—Dizziness—Etoposide—lung cancer	0.000247	0.0006	CcSEcCtD
Hydralazine—Body temperature increased—Docetaxel—lung cancer	0.000246	0.000596	CcSEcCtD
Hydralazine—Leukopenia—Methotrexate—lung cancer	0.000246	0.000596	CcSEcCtD
Hydralazine—Chills—Doxorubicin—lung cancer	0.000245	0.000594	CcSEcCtD
Hydralazine—Dizziness—Paclitaxel—lung cancer	0.000243	0.000588	CcSEcCtD
Hydralazine—Nausea—Cisplatin—lung cancer	0.000243	0.000588	CcSEcCtD
Hydralazine—Vomiting—Etoposide—lung cancer	0.000238	0.000577	CcSEcCtD
Hydralazine—Rash—Etoposide—lung cancer	0.000236	0.000572	CcSEcCtD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—lung cancer	0.000236	0.00265	CbGpPWpGaD
Hydralazine—Dermatitis—Etoposide—lung cancer	0.000236	0.000571	CcSEcCtD
Hydralazine—Headache—Etoposide—lung cancer	0.000234	0.000568	CcSEcCtD
Hydralazine—Arthralgia—Methotrexate—lung cancer	0.000234	0.000567	CcSEcCtD
Hydralazine—Myalgia—Methotrexate—lung cancer	0.000234	0.000567	CcSEcCtD
Hydralazine—Vomiting—Paclitaxel—lung cancer	0.000233	0.000565	CcSEcCtD
Hydralazine—Rash—Paclitaxel—lung cancer	0.000231	0.000561	CcSEcCtD
Hydralazine—Dermatitis—Paclitaxel—lung cancer	0.000231	0.00056	CcSEcCtD
Hydralazine—Discomfort—Methotrexate—lung cancer	0.000231	0.00056	CcSEcCtD
Hydralazine—Headache—Paclitaxel—lung cancer	0.00023	0.000557	CcSEcCtD
Hydralazine—Hypersensitivity—Docetaxel—lung cancer	0.000229	0.000555	CcSEcCtD
Hydralazine—Muscle spasms—Doxorubicin—lung cancer	0.000229	0.000554	CcSEcCtD
Hydralazine—CYP3A4—Tryptophan metabolism—CYP2E1—lung cancer	0.000226	0.00254	CbGpPWpGaD
Hydralazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—lung cancer	0.000225	0.00252	CbGpPWpGaD
Hydralazine—Nausea—Etoposide—lung cancer	0.000222	0.000539	CcSEcCtD
Hydralazine—Ill-defined disorder—Doxorubicin—lung cancer	0.000221	0.000535	CcSEcCtD
Hydralazine—Pruritus—Docetaxel—lung cancer	0.00022	0.000533	CcSEcCtD
Hydralazine—Anaemia—Doxorubicin—lung cancer	0.00022	0.000533	CcSEcCtD
Hydralazine—Thrombocytopenia—Methotrexate—lung cancer	0.000219	0.000532	CcSEcCtD
Hydralazine—Agitation—Doxorubicin—lung cancer	0.000219	0.00053	CcSEcCtD
Hydralazine—Nausea—Paclitaxel—lung cancer	0.000218	0.000528	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—lung cancer	0.000215	0.00241	CbGpPWpGaD
Hydralazine—Malaise—Doxorubicin—lung cancer	0.000214	0.00052	CcSEcCtD
Hydralazine—Anorexia—Methotrexate—lung cancer	0.000214	0.000518	CcSEcCtD
Hydralazine—Leukopenia—Doxorubicin—lung cancer	0.000213	0.000516	CcSEcCtD
Hydralazine—Diarrhoea—Docetaxel—lung cancer	0.000213	0.000516	CcSEcCtD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—lung cancer	0.000212	0.00238	CbGpPWpGaD
Hydralazine—Palpitations—Doxorubicin—lung cancer	0.00021	0.000509	CcSEcCtD
Hydralazine—Hypotension—Methotrexate—lung cancer	0.000209	0.000508	CcSEcCtD
Hydralazine—Dizziness—Docetaxel—lung cancer	0.000206	0.000499	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000204	0.000495	CcSEcCtD
Hydralazine—Arthralgia—Doxorubicin—lung cancer	0.000202	0.000491	CcSEcCtD
Hydralazine—Myalgia—Doxorubicin—lung cancer	0.000202	0.000491	CcSEcCtD
Hydralazine—Anxiety—Doxorubicin—lung cancer	0.000202	0.000489	CcSEcCtD
Hydralazine—Paraesthesia—Methotrexate—lung cancer	0.000201	0.000488	CcSEcCtD
Hydralazine—Discomfort—Doxorubicin—lung cancer	0.0002	0.000485	CcSEcCtD
Hydralazine—Dyspnoea—Methotrexate—lung cancer	0.0002	0.000484	CcSEcCtD
Hydralazine—Vomiting—Docetaxel—lung cancer	0.000198	0.000479	CcSEcCtD
Hydralazine—Dyspepsia—Methotrexate—lung cancer	0.000197	0.000478	CcSEcCtD
Hydralazine—Rash—Docetaxel—lung cancer	0.000196	0.000475	CcSEcCtD
Hydralazine—Dermatitis—Docetaxel—lung cancer	0.000196	0.000475	CcSEcCtD
Hydralazine—Decreased appetite—Methotrexate—lung cancer	0.000195	0.000472	CcSEcCtD
Hydralazine—Headache—Docetaxel—lung cancer	0.000195	0.000472	CcSEcCtD
Hydralazine—Oedema—Doxorubicin—lung cancer	0.000194	0.00047	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Methotrexate—lung cancer	0.000194	0.000469	CcSEcCtD
Hydralazine—Thrombocytopenia—Doxorubicin—lung cancer	0.00019	0.000461	CcSEcCtD
Hydralazine—Tachycardia—Doxorubicin—lung cancer	0.000189	0.000459	CcSEcCtD
Hydralazine—Anorexia—Doxorubicin—lung cancer	0.000185	0.000448	CcSEcCtD
Hydralazine—Nausea—Docetaxel—lung cancer	0.000185	0.000448	CcSEcCtD
Hydralazine—Feeling abnormal—Methotrexate—lung cancer	0.000185	0.000448	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—lung cancer	0.000183	0.00205	CbGpPWpGaD
Hydralazine—Hypotension—Doxorubicin—lung cancer	0.000181	0.00044	CcSEcCtD
Hydralazine—CYP3A4—Tryptophan metabolism—CAT—lung cancer	0.000181	0.00204	CbGpPWpGaD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—lung cancer	0.00018	0.00203	CbGpPWpGaD
Hydralazine—Urticaria—Methotrexate—lung cancer	0.000178	0.000432	CcSEcCtD
Hydralazine—Body temperature increased—Methotrexate—lung cancer	0.000177	0.00043	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000177	0.000429	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—CNDP2—lung cancer	0.000176	0.00198	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTM2—lung cancer	0.000176	0.00198	CbGpPWpGaD
Hydralazine—Paraesthesia—Doxorubicin—lung cancer	0.000174	0.000422	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—lung cancer	0.000174	0.00196	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTM2—lung cancer	0.000174	0.00195	CbGpPWpGaD
Hydralazine—Dyspnoea—Doxorubicin—lung cancer	0.000173	0.000419	CcSEcCtD
Hydralazine—Dyspepsia—Doxorubicin—lung cancer	0.000171	0.000414	CcSEcCtD
Hydralazine—Decreased appetite—Doxorubicin—lung cancer	0.000169	0.000409	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000168	0.000406	CcSEcCtD
Hydralazine—Constipation—Doxorubicin—lung cancer	0.000166	0.000402	CcSEcCtD
Hydralazine—Hypersensitivity—Methotrexate—lung cancer	0.000165	0.0004	CcSEcCtD
Hydralazine—CYP3A4—Tryptophan metabolism—CYP1A1—lung cancer	0.000162	0.00182	CbGpPWpGaD
Hydralazine—Feeling abnormal—Doxorubicin—lung cancer	0.00016	0.000388	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—CYP2A7—lung cancer	0.000159	0.00179	CbGpPWpGaD
Hydralazine—Pruritus—Methotrexate—lung cancer	0.000159	0.000384	CcSEcCtD
Hydralazine—CYP3A4—Metapathway biotransformation—CYP2A7—lung cancer	0.000157	0.00176	CbGpPWpGaD
Hydralazine—Urticaria—Doxorubicin—lung cancer	0.000154	0.000374	CcSEcCtD
Hydralazine—Body temperature increased—Doxorubicin—lung cancer	0.000153	0.000372	CcSEcCtD
Hydralazine—Diarrhoea—Methotrexate—lung cancer	0.000153	0.000372	CcSEcCtD
Hydralazine—Dizziness—Methotrexate—lung cancer	0.000148	0.000359	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—lung cancer	0.000148	0.00166	CbGpPWpGaD
Hydralazine—Hypersensitivity—Doxorubicin—lung cancer	0.000143	0.000347	CcSEcCtD
Hydralazine—Vomiting—Methotrexate—lung cancer	0.000143	0.000345	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—GSTA3—lung cancer	0.000142	0.00159	CbGpPWpGaD
Hydralazine—Rash—Methotrexate—lung cancer	0.000141	0.000343	CcSEcCtD
Hydralazine—Dermatitis—Methotrexate—lung cancer	0.000141	0.000342	CcSEcCtD
Hydralazine—Headache—Methotrexate—lung cancer	0.00014	0.00034	CcSEcCtD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTA3—lung cancer	0.00014	0.00157	CbGpPWpGaD
Hydralazine—Pruritus—Doxorubicin—lung cancer	0.000137	0.000333	CcSEcCtD
Hydralazine—Nausea—Methotrexate—lung cancer	0.000133	0.000323	CcSEcCtD
Hydralazine—Diarrhoea—Doxorubicin—lung cancer	0.000133	0.000322	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—lung cancer	0.000131	0.00147	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTA4—lung cancer	0.00013	0.00146	CbGpPWpGaD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—lung cancer	0.000129	0.00146	CbGpPWpGaD
Hydralazine—Dizziness—Doxorubicin—lung cancer	0.000128	0.000311	CcSEcCtD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTA4—lung cancer	0.000128	0.00144	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTA2—lung cancer	0.000127	0.00142	CbGpPWpGaD
Hydralazine—Vomiting—Doxorubicin—lung cancer	0.000123	0.000299	CcSEcCtD
Hydralazine—Rash—Doxorubicin—lung cancer	0.000122	0.000297	CcSEcCtD
Hydralazine—Dermatitis—Doxorubicin—lung cancer	0.000122	0.000296	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—GSTA1—lung cancer	0.000122	0.00137	CbGpPWpGaD
Hydralazine—Headache—Doxorubicin—lung cancer	0.000122	0.000295	CcSEcCtD
Hydralazine—Nausea—Doxorubicin—lung cancer	0.000115	0.000279	CcSEcCtD
Hydralazine—CYP3A4—Metapathway biotransformation—AKR1C1—lung cancer	0.000115	0.0013	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—UGT1A1—lung cancer	0.000113	0.00128	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—UGT1A1—lung cancer	0.000112	0.00126	CbGpPWpGaD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—lung cancer	0.000106	0.0012	CbGpPWpGaD
Hydralazine—CYP3A4—Tryptophan metabolism—MDM2—lung cancer	0.0001	0.00112	CbGpPWpGaD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—lung cancer	9.78e-05	0.0011	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—HPGDS—lung cancer	9.65e-05	0.00108	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTT1—lung cancer	9.36e-05	0.00105	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—CYP2A6—lung cancer	9.25e-05	0.00104	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GCLC—lung cancer	9.25e-05	0.00104	CbGpPWpGaD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—POMC—lung cancer	7.93e-05	0.000891	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—CYP2E1—lung cancer	7.86e-05	0.000884	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—CYP2E1—lung cancer	7.76e-05	0.000872	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTP1—lung cancer	6.49e-05	0.000729	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTP1—lung cancer	6.4e-05	0.000719	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTM1—lung cancer	5.96e-05	0.00067	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTM1—lung cancer	5.88e-05	0.000661	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—CYP1A1—lung cancer	5.65e-05	0.000635	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—CYP1A1—lung cancer	5.57e-05	0.000626	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—COL4A3BP—lung cancer	4.97e-05	0.000559	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—AZIN2—lung cancer	4.97e-05	0.000559	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ATP5H—lung cancer	4.23e-05	0.000475	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—POMC—lung cancer	4.21e-05	0.000473	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PLBD1—lung cancer	3.77e-05	0.000423	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HSD17B10—lung cancer	3.44e-05	0.000387	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CKB—lung cancer	3.2e-05	0.00036	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTM2—lung cancer	3.01e-05	0.000338	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CNDP2—lung cancer	3.01e-05	0.000338	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—MTMR3—lung cancer	2.93e-05	0.000329	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PGAM1—lung cancer	2.85e-05	0.000321	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP2A7—lung cancer	2.72e-05	0.000306	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SDC4—lung cancer	2.66e-05	0.000299	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—RRM1—lung cancer	2.43e-05	0.000273	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTA3—lung cancer	2.43e-05	0.000273	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—B4GALT5—lung cancer	2.28e-05	0.000256	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTA4—lung cancer	2.22e-05	0.000249	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTA2—lung cancer	2.16e-05	0.000243	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTA1—lung cancer	2.09e-05	0.000235	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ABCC3—lung cancer	2.06e-05	0.000232	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—AKR1C1—lung cancer	2e-05	0.000225	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—UGT1A1—lung cancer	1.94e-05	0.000218	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GNG11—lung cancer	1.87e-05	0.00021	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ALDOA—lung cancer	1.78e-05	0.0002	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NCOA3—lung cancer	1.73e-05	0.000194	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ADCY1—lung cancer	1.68e-05	0.000189	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ABCG2—lung cancer	1.68e-05	0.000189	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HPGDS—lung cancer	1.65e-05	0.000185	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ENO2—lung cancer	1.65e-05	0.000185	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PPP2R1B—lung cancer	1.64e-05	0.000184	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTT1—lung cancer	1.6e-05	0.00018	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GCLC—lung cancer	1.58e-05	0.000178	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP2A6—lung cancer	1.58e-05	0.000178	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ENO1—lung cancer	1.5e-05	0.000169	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP2E1—lung cancer	1.34e-05	0.000151	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NQO1—lung cancer	1.33e-05	0.000149	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—STK11—lung cancer	1.2e-05	0.000135	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTP1—lung cancer	1.11e-05	0.000125	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CAT—lung cancer	1.08e-05	0.000121	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ABCB1—lung cancer	1.05e-05	0.000118	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—TYMS—lung cancer	1.03e-05	0.000116	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTM1—lung cancer	1.02e-05	0.000115	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP1A1—lung cancer	9.66e-06	0.000109	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ERCC2—lung cancer	9.58e-06	0.000108	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—APOA1—lung cancer	8.29e-06	9.32e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3CG—lung cancer	7.57e-06	8.51e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—POMC—lung cancer	7.2e-06	8.1e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CREBBP—lung cancer	7.02e-06	7.89e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3CD—lung cancer	6.65e-06	7.48e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ALB—lung cancer	6.57e-06	7.38e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3CB—lung cancer	5.8e-06	6.52e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PTGS2—lung cancer	5.75e-06	6.46e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PTEN—lung cancer	5.01e-06	5.63e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—EP300—lung cancer	4.78e-06	5.37e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3CA—lung cancer	3.54e-06	3.97e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—AKT1—lung cancer	2.89e-06	3.25e-05	CbGpPWpGaD
